RB Capital Management LLC Grows Position in Eli Lilly and Company (NYSE:LLY)

RB Capital Management LLC raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 12.8% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 2,486 shares of the company’s stock after purchasing an additional 282 shares during the period. RB Capital Management LLC’s holdings in Eli Lilly and Company were worth $1,449,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Orion Capital Management LLC increased its holdings in Eli Lilly and Company by 18.7% during the fourth quarter. Orion Capital Management LLC now owns 1,584 shares of the company’s stock valued at $923,000 after buying an additional 250 shares during the period. Concord Wealth Partners boosted its position in Eli Lilly and Company by 20.3% during the 4th quarter. Concord Wealth Partners now owns 3,644 shares of the company’s stock valued at $2,124,000 after acquiring an additional 615 shares in the last quarter. DiNuzzo Private Wealth Inc. purchased a new position in shares of Eli Lilly and Company in the 4th quarter valued at $69,000. Mitsubishi UFJ Morgan Stanley Securities Co. Ltd. purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth $685,000. Finally, Triumph Capital Management boosted its position in Eli Lilly and Company by 164.2% during the fourth quarter. Triumph Capital Management now owns 2,240 shares of the company’s stock valued at $1,305,000 after purchasing an additional 1,392 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.6 %

Shares of Eli Lilly and Company stock traded down $4.35 during trading hours on Wednesday, hitting $776.75. The company had a trading volume of 2,762,200 shares, compared to its average volume of 3,059,053. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The company’s 50-day moving average is $761.41 and its two-hundred day moving average is $669.21. The company has a market cap of $738.04 billion, a P/E ratio of 133.47, a price-to-earnings-growth ratio of 1.61 and a beta of 0.34. Eli Lilly and Company has a twelve month low of $399.26 and a twelve month high of $800.78.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, April 30th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. During the same quarter in the prior year, the firm posted $1.62 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 26.0% on a year-over-year basis. Analysts anticipate that Eli Lilly and Company will post 12.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on LLY. Morgan Stanley lifted their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Truist Financial increased their price objective on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a research note on Wednesday. BMO Capital Markets lifted their price objective on Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, Barclays upped their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 7th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $742.95.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.